GO
Loading...

Pharmaceuticals

More

  • Biotech drug maker ImClone Systems  and drug maker Bristol-Myers Squibb said Wednesday data shows their cancer drug Erbitux, when combined with chemotherapy, allows head and neck cancer patients to live longer.

  • U.K. Watchdog to Probe Pfizer, Boots Medicines Deal Wednesday, 4 Apr 2007 | 3:07 AM ET

    Britain's consumer affairs watchdog said on Wednesday it would investigate the U.K. market for distributing medicines after drugs giant Pfizer  struck a deal to sell its products through a single wholesaler.

  • Biopharmaceutical company Theravance Inc. said Monday it saw positive results from two midstage studies dealing with its developing asthma and chronic obstructive pulmonary disease treatments.

  • What If Iran Goes Awry? Monday, 2 Apr 2007 | 6:42 PM ET

    Iranian mischief is the single most bankable trend in the world, Cramer says. So he’s got a doomsday portfolio for you just in case events take a turn for the worst. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Webcast: Weekly Winner John T. On Strategy Monday, 2 Apr 2007 | 1:24 PM ET

    Our Monday webcast featured our new weekly winner, John Tepechin. He's weekly winner number 4 (this is the start of week five). John talked with CNBC's Dylan Ratigan about his picks. John said his strategy was to go all in. He picked BSTE, because he thought it was buyout material. Why did he think that? He said it was from reading the news...

  • Ads for Pfizer Inc.'s  Celebrex arthritis drug are set to splash across U.S. television screens on Monday after more than a two-year hiatus, with an unusual upfront focus on its risks rather than its benefits.

  • Shares of Italy’s Pirelli soared to 9.67% Monday morning after it revealed late Sunday that it was in talks with U.S. telecom giant AT&T and its Mexican affiliate America Movil to sell two-thirds of its 80% stake in holding company Olimpia for 2.82 euros a share less debt.

  • Celesio Mulling Alliance Boots Bid Monday, 2 Apr 2007 | 6:32 AM ET

    Celesio, the German owner of the Lloyds pharmacy chain, is exploring a possible offer to buy rival Alliance Boots, people familiar with the situation said on Monday.

  • Novartis Pulls Zelnorm in U.S., Cuts 2007 Outlook Monday, 2 Apr 2007 | 2:08 AM ET

    Novartis pulled bowel drug Zelnorm from U.S. shelves on Friday at the request of regulators because clinical trial data indicated a possible link to heart attacks and strokes.

  • Novartis cut its 2007 sales forecast on Friday after pulling bowel drug Zelnorm from U.S. shelves at the request of regulators because clinical trial data indicated a possible link to heart attacks and strokes.

  • Shares of Dendreon shot up after a panel of FDA advisers voted Provenge is both safe and effective in treating advanced prostate cancer.

  • Shares of Dendreon are up about 250% in pre-market trading after a panel of FDA advisers voted Provenge is both safe and effective in treating advanced prostate cancer.

  • Deborah Taft Still Leads--Number Two Changes Hands Friday, 30 Mar 2007 | 10:06 AM ET

    Good morning all. Deborah Taft continues to hold the top position, but she is losing ground. And there's a new number two; Jason Kaplan. Jason gains 2nd place on his Worthington Industries trade forcing Chad Mazeika into 3rd place with only small gains on Mariner Energy and Sonus.

  • Dendreon Does It Friday, 30 Mar 2007 | 9:37 AM ET

    An FDA Advisory Committee voted 17-0 saying Dendreon's Provenge for prostate cancer is "reasonably safe". And it voted 13-4 saying there's "substantial evidence" that it's efficacious. At first the efficacy question was phrased by the FDA like this: "Does the submitted data establish the efficacy of (Provenge) in the intended population?" Call it semantics, but as they started going around the room it sounded like it might go down with that language.

  • GlaxoSmithKline  said Thursday it has submitted a biologics license application for Cervarix, its cervical cancer candidate vaccine, to the U.S. Food and Drug Administration.

  • Stocks: Which Ones Are Paying Off...And Not Thursday, 29 Mar 2007 | 10:08 AM ET

    Hi folks. Here a look at the latest stock performance. Quick turnarounds seem to be paying off for several stocks, but obviously, not all. Downgrades and business news (see Beazer Homes below) certainly affect what's happening. Note the "replacements" at the S&P in the first paragraph. Okay, here are the stats with some notes on why the stocks are where they are.

  • Battle Brewing For Top Spot On Leaderboard Thursday, 29 Mar 2007 | 9:28 AM ET

    Good morning. Deborah Taft and Chad Mazeika maintain their stranglehold on the two top positions of the Leaderboard. Deborah continues in the lead with a portfolio value of $2,585,726.30 up $3k from Tuesday's total of $2,582,726.3 on bonus bucks alone. After Deborah's trade on CVTX she was all in cash before executing two buys Wednesday...

  • Embargo-gate at the ACC Wednesday, 28 Mar 2007 | 6:19 PM ET

    Embargo-gate at the ACC Scientific journals and medical groups employ media embargoes on studies that are to be published or presented. The common practice gives reporters like me a chance to read and digest the information in advance, interview researchers and experts, maybe talk to patients so that when the embargo lifts full and accurate stories will air, run in the papers or cross the wires. It also gives the journals and medical groups a way to manage the news cycle and get more media bang for their publication or conference. Such was supposed to be the case at this week's American College of Cardiology conference in New Orleans.

  • Dendreon Shares Take Off Ahead of FDA Panel Meeting Wednesday, 28 Mar 2007 | 4:07 PM ET

    Shares of pharmaceutical firm Dendreon leaped on Wednesday following a CNBC report about a planned Thursday Food and Drug Administration hearing that could determine the fate of a prostate cancer drug from the company.

  • Deborah Taft Still On Top--But New Number Two Wednesday, 28 Mar 2007 | 8:50 AM ET

    Good morning. Deborah Taft continues in the lead with a portfolio value of $2,582,726.3, up $366,000 Tuesday, from Monday's value of $2,216,726.30. Deborah's gamble on the ever-active CV Therapeutics paid off and secured her lead position. She went all in on Monday with a buy of 300,000 shares of CVTX at $6.75, and it looks like she caught a bottom...